Myriad Genetics price target increased to $48 from $39 at Stephens Stephens said a recent meeting with Myriad Genetics' management makes the firm more bullish on the near-term and long-term prospects for the company. The firm raised its price target on the stock to $48 and reiterates its Overweight rating on the shares.
Myriad Genetics, Tufts Health Plan sign agreement to cover Prolaris Myriad Genetics announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality. Tufts Health Plan is a leading health plan in the Northeast with more than one million members. Tufts Health Plan's members will benefit from this agreement, which is designed to drive optimal treatment because men can confidently pursue active surveillance for tumors identified as being less aggressive with Myriad's extensively validated Prolaris combined score. Recent data show that many men realize no benefit from interventional treatment, and many suffer needlessly from the side effects associated with radical prostatectomy and radiation.